The Efficacy Analysis Of Early Postoperative Continuous Hyperthermic Peritoneal Perfusion Chemotherapy Combined With Intravenous Chemotherapy For Colon Cancer

Objective:To observe the difference effects between early postoperative hyperthermicintraperitoneal perfusion chemotherapy combined with venous chemotherapy andconventional intravenous chemotherapy on the patients’ treatment; To compare theeffect of two methods of treatment on immune function in patients with Coloncancer， in order to seek more reasonable and comprehensive treatment program forcolon cancer to provide clinical basis for the further treatment.Methods:Our department has chosen111cases of surgery patients with cancer of colonfrom September28,2010to September30,2012. They are divided into two groupsaccording to the random number. The patients in experimental group are acceptedCHPPC with PDD in one or two days after the operation, the treatment temperature ismaintained between42℃and43℃and the duration is from60to90minutes. Boththe experimental group and control group are all accepted intravenous chemotherapywith the same standard chemotherapeutic regimen after the operation of two weeks.The difference of effect is compared with statistical analysis(X2text or t test) after twochemotherapy cycle before and after the treatment. The two groups are respectively abstracted serum samples to exam the subsets of T cells and NK cells whether thereare changes of immune function of two groups before and after the treatment iscompared(t test).To compare the time to progression and overall survival of twogroups.Results:1.The process of the CHPPC don’t have an obvious effect on patients’ vitalsigns; Adverse reaction compared with control group with no statistical significance(P>0.05); the improvement of life quality of experimental group is more significantthan the control group, with statistically significant difference (P <0.01); the localrecurrence rate of experimental group is significant lower than the control group, withstatistically significant difference (P <0.01); the incidence of liver metastasis ofexperimental group is lower than control group, with statistical significance(P <0.05); Two sets of CEA, CA19-9, CA242water dropped by an average of thedifferences were statistically significant (P <0.05) compared with before treatment,and the CEA, CA19-9, CA242index of the experimental group are significantly lowerthan the control group after treatment, which the difference was statisticallysignificant (P <0.01).2. Patients of the two groups were respectively accepted with fasting venousblood to test T lymphocyte subsets and NK cells before and after the treatment. thencompare them by T test. the value of CD3+, CD4+, CD4+/CD8+of the experimentalgroup gained compared with before treatment，while the value of CD8+reduced.Which is significant statistical significance(P<0.01); the value of CD3+, CD8+,CD4+/CD8+，NK of control group has no obvious changes before and after thetreatment, with no statistical significance(P>0.05).Conclusion:1. There is no significant effect on vital signs of the early postoperative patientstreated with CHPPC after colon cancer surgery. The course of treatment is safe and feasible.2. The patients with colon cancer early postoperative intraperitoneal circulationperfusion chemotherapy combined with intravenous chemotherapy can not onlyimprove colon cancer patients’ quality of life but also reduce the rate of localrecurrence and liver metastasis of colon cancer patients.3. Compared with venous chemotherapy, CHPPC combined with venouschemotherapy can improve the immune function of patients with gastric cancer.